Autonomous Nanomedicine: Closing the Biological Validation Gap

ABSTRACT

Although nanomedicines offer advanced formulation control and physicochemical characterization, clinical translation has been limited. Delivery meta‐analyses and late‐stage attrition indicate biological validation is often a bottleneck. It must account for context‐dependent processes such as protein corona formation, immune recognition and cell/tissue barrier effects, which standard preclinical testing cannot always assess adequately. To address this, we propose a Design–Make–Test–Biology–Learn (DMTBL) workflow that separates biological validation from physicochemical testing and feeds human‐relevant biological results back into formulation design. We assess the capabilities required for end‐to‐end autonomy using an author‐assigned technology‐readiness evaluation with explicit criteria adapted for biomedical translation. Many of the required technologies are approaching practical deployment, including high‐throughput robotic formulation, automated physicochemical assays, predictive models for biodistribution and toxicity, and patient‐derived organoids with growing human relevance. But no closed‐loop DMTBL system has yet been demonstrated: integration sits at technology readiness level 2–3 against components at levels 3–8. The Learn step also requires a different computational stack from the Analyze step it replaces, handling imaging and multi‐parametric phenotypes rather than scalar physicochemical metrics. Three practical barriers remain: mismatched timescales between formulation and biological testing, heterogeneous data combining quantitative measurements with imaging and biological variability across platforms and donors. We set out near‐term engineering and standardization priorities within a staged roadmap that separates plausible short‐term milestones from longer‐horizon goals.